Get started

Coronaviruscure

Corona death analyses in GermanyWelcome to my Corona Death Analysis *Note because the chart was inserted as an image, the scaling may have shifted slightly, simply scale at the right edge until the orange zero matches the zero line of the chart. First of all, I know Corona is a delicate subject and also that I analyze the deaths here seems to work a macabre, but the fact is that the numbers are rising and this can have an impact on the German economy, this analysis serves as a complement to my DAX short analysis and is purely scientific nature. The Dax analysis can be found here (German Only) Let's get to the analysis: As we can see from the chart, deaths increased rapidly between January and February, reaching a high of ca 1138. In February, a bearish SKS formed at the high which had also already reached its target of 371 deaths. This target line is very often reached again after the Unterstreiten in later upward movements or correction phases and serves us thus as a first "target line" Furthermore, we can take from the chart an ABC Correct which has the following death numbers as a target. Target 1 435 Target 2 705 Target 3 900 Target 4 1451 Target 5 1846 Here the death number of 900 is to be seen as the first strong resistance. At 1451 I expect the end of the rising numbers for the first time, whereas 1846 deaths would be the maximum and at the latest here a trend reversal should take place. If you liked this idea, I would be pleased about a click on the Like button ;) If you have any questions, suggestions or a different opinion, don't be afraid to use the comment function. Thanks a lot Disclaimer: Please keep in mind that this is a pure analysis and only reflects what my eye shows me ;) This analysis is for informational purposes only and is scientific in nature. This analysis is not based on any fundamental data! This analysis is not an investment advice and should not be considered as a buy, sell or hold signal. Always do your own research before investing and seek the advice of a qualified person. I am not an investment advisor or similar and do not make any investment recommendation here.
TSE:5909Long
by Highrisk221
DJI: Trump's Covid-19 Case - A Historical ComparisonIn this analysis I'll be shedding light on my own theory on: - How President Trump's Covid-19 Positive news may impact the market - Similarities and differences in historic cases - Why Trump possibly announced his testing positive so quickly Trump's Testing Positive - Trump testing positive for Covid-19, 4 weeks before the presidential elections, is not good news - Especially considering that the current market is momentum driven, such bad news is good enough to scare new investors from pouring money into the market We can see a similar case where the president's medical condition negatively impacted the market Historic case - President Eisenhower suffered a heart attack in September 25, 1955. - Before this incident, the stock market was at an unprecedented bullish rally - Immediately after news was released that he was hospitalized, the market fell by 6%, leading to $14 billion instantly vanishing - Eisenhower recovered, and it was later announced that his condition was not serious - Eventually, the market bounced, and continued to rally upwards - President Trump also announced his testing positive for Covid-19 a few hours ago - Just as Eisenhower's case, the stock market is in an uptrend, with significant bullish momentum - The market is correcting, due to bad news, but not as significantly as that of the past - Just as Eisenhower, considering the fact that Trump will be taken care of seriously, it's most likely that he will recover from the virus - As such, it's reasonable to expect that the market will continue to rally upwards - However, it's also important to consider that market situations are not the same as the past - For more in-depth explanation on what makes today's market special, check out my previous analysis below: Why did Trump announce his condition? - This is an important question to ask, as Trump announced his testing positive for Covid via twitter - Trump is arguably the most powerful person in the world. He could have concealed his condition if he really wanted to, and later justify it as "classified information" - What could have been Trump's intentions behind this? - In the case of the Prime Minister of the UK, Boris Johnson, his support rate was at 48% prior to him testing positive - After he got the virus, there was a sentiment of sympathy among the general public, leading to his support rate skyrocketing to 72%, an all time high support rate ever since Tony Blair - Given this case, and the fact that the presidential elections will be held in 4 weeks, Trump could have been targeting this sympathetic sentiment among the general public - It's also highly likely that Trump recovers quickly, with the best medical staff from the country treating him - As such, he will be qualified to talk about the issue (as someone who has caught the virus), and suggest that he's the only one capable of solving the problem. Conclusion As past cases demonstrate, problems regarding the President's medical condition is never good for the market. However, given that the president recovers quickly, this could end up being a 'buy the dip' opportunity. If you like this analysis, please make sure to like the post, and follow for more quality content! I would also appreciate it if you could leave a comment below with some original insight.
Editors' picks
TVC:DJIEducation
by Michael_Wang_Official
79
$COCP Clears the Runway for a $10+ move In the coming daysBOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage Biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program. finance.yahoo.com “Following our acquisition of patent rights and know-how from KSURF and our recently completed financing, we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform. Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development. We will seek opportunities for collaborations as we advance our programs,” stated Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. Cocrystal recently entered into a license agreement with KSURF to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. For additional information about the Company’s development pipeline, please visit www.cocrystalpharma.com. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com. COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. “We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.” Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
NASDAQ:COCPLong
by StockGuild